Clinical Trials Browser

Suspended × Melanoma × Magnetic Resonance Spectroscopy × Clear all

NCT05764395 2024-10-10

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Phase 2 Suspended

Melanoma